Novartis Licenses Abogen RNA Drug in $575 Million Upfront Deal Novartis agreed to pay Abogen $575 million upfront for worldwide rights to ABO2203 and options...

https://www.narrowit.com/news/abogen-novartis-rna-license-575-million-2026-10-04
#AbogenBiosciences #Novartis #ABO2203 #MrnaTherapeutics

#Novartis has added a #Tcellengager (TCE) developed by China's #AbogenBiosciences for #autoimmunedisorders in a deal that could be worth over $7.5 billion.

buff.ly/XBf4uCh